Biocryst Pharmaceuticals diskutieren
Biocryst Pharmaceuticals
WKN: 896047 / Symbol: BCRX / Name: Biocryst Pharm / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
6,41 €
0,60 %
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $11.00 price target on the stock, up previously from $10.00.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $11.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $20.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at Needham & Company LLC from $15.00 to $17.00. They now have a "buy" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $13.00. They now have an "overweight" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $13.00 price target on the stock, up previously from $11.00.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $17.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at Wedbush from $16.00 to $18.00. They now have an "outperform" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank Of Canada. They now have a $13.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at Bank of America Corporation from $13.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $30.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Needham & Company LLC from $17.00 to $20.00. They now have a "buy" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Cantor Fitzgerald from $24.00 to $26.00. They now have an "overweight" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for BCRX provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Establishment Labs Holdings Inc diskutieren